• Drishti Banerjee

Pharmaceutical trademarks perform a role greater than product identification and goodwill protection as they have a direct nexus with public health. Deceptive similarities in such trademarks that might lead to confusion may endanger public interest at large. Naming drugs is a technically challenging process given the system of scientific non-proprietary nomenclature based on active pharmaceutical ingredients (APIs). When a drug contains more than one API, the availability of combinations becomes limited. Brand names, mostly based on generic names for their simplicity and consistency, face the challenge of limited distinctiveness. Certain practices including counterfeiting, generic substitution, or parallel imports further complicate the scenario, depriving the owners of trademarks of their fair share of protection and economic benefits. Conflicting perspectives on pharmaceutical trademarks need to be reconciled with an appropriate collaboration among the concerned departments and regulatory mechanisms in order to deal with the problem at hand.

Pharmaceutical Trademarks, Generic Substitution, Parallel Imports, INNs, Public Health.

"Pharmaceutical Trademarks And Inns: Issues And Challenges In Light Of Public Health", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 3, page no.j736-j742, March-2024, Available :http://www.jetir.org/papers/JETIR2403994.pdf

"Pharmaceutical Trademarks And Inns: Issues And Challenges In Light Of Public Health", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 3, page no. ppj736-j742, March-2024, Available at : http://www.jetir.org/papers/JETIR2403994.pdf